PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery - Contacts and Locations

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

This study is ongoing, but not recruiting participants.

Study NCT00365053. Last updated on October 24, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00365053

Locations


United States, California
	City of Hope Comprehensive Cancer Center
	Duarte, California, United States, 91010-3000
	City of Hope Medical Group
	Pasadena, California, United States, 91105
	Contra Costa Regional Medical Center
	Martinez, California, United States, 94553
	Tower Cancer Research Foundation
	Beverly Hills, California, United States, 90211
	University of California Davis Cancer Center
	Sacramento, California, United States, 95817
	USC/Norris Comprehensive Cancer Center and Hospital
	Los Angeles, California, United States, 90089-9181
	Veterans Affairs Outpatient Clinic - Martinez
	Martinez, California, United States, 94553

United States, Pennsylvania
	Hillman Cancer Center at University of Pittsburgh Cancer Institute
	Pittsburgh, Pennsylvania, United States, 15232

Sponsors and Collaborators

California Cancer Consortium

National Cancer Institute (NCI)

Investigators


Study Chair:	Suresh Ramalingam, MD	Emory University